As part of its next stage of growth, Rani Therapeutics recently hired Robert Gaffney as Vice President of Operations to lead the company's expansion.Gaffney joined from Spinal Modulation, an InCube Labs company acquired by St. Jude Medical in 2015, where he served as Chief Operating Officer.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.715 USD | +0.75% | +2.50% | +42.02% |
05-16 | UBS Adjusts Rani Therapeutics Price Target to $8 From $4, Maintains Buy Rating | MT |
05-07 | HC Wainwright Adjusts Price Target on Rani Therapeutics Holdings to $13 From $12, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.02% | 123M | |
+15.19% | 121B | |
+13.38% | 107B | |
-5.46% | 24.82B | |
+1.75% | 22.48B | |
-10.09% | 18.32B | |
-42.28% | 16.33B | |
-15.57% | 15.31B | |
+3.19% | 14.08B | |
+25.17% | 11.74B |
- Stock Market
- Equities
- RANI Stock
- News Rani Therapeutics Holdings, Inc.
- Rani Therapeutics Hires Robert Gaffney as Vice President of Operations